Key result
Anti-inflammatory therapies show promise for treating ischemic heart disease by modulating the NLRP3 inflammasome.
Why the study?
Immunomodulatory strategies targeting the NLRP3 inflammasome have gained support in ischemic heart disease, prompting an updated review of these approaches across the disease continuum.
Do anti-inflammatory therapies targeting the NLRP3 inflammasome improve outcomes in patients with ischemic heart disease?
Do anti-inflammatory therapies targeting the NLRP3 inflammasome improve outcomes in patients with ischemic heart disease?
Answers are grounded in this paper and cite their sources.
This review underscores the central role of the NLRP3 inflammasome in ischemic heart disease and highlights colchicine, interleukin modulators, and SGLT2 inhibitors as promising immunomodulatory therapies.
PURPOSE OF REVIEW: The inclusion of immunomodulatory strategies as supportive therapies in ischemic heart disease (IHD) has garnered significant support over recent years. Several such approaches appear to be unified through their ultimate target, the NLRP3 inflammasome. This review presents a brief update on immunomodulatory strategies in the continuum of conditions constituting ischemic heart disease and emphasising on the seemingly unifying mechanism of NLRP3 activation as well as modulation across these conditions. RECENT FINDINGS: The NLRP3 inflammasome is a multiprotein complex assembled upon inflammatory stimulation, causing the release of pro-inflammatory cytokines and initiating pyroptosis. The NLRP3 pathway is relevant in inflammatory signalling of cardiac immune cells as well as non-immune cells in the myocardium, including cardiomyocytes, fibroblasts and endothelial cells. In addition to a focus on clinical outcome and efficacy trials of targeting NLRP3-related pathways, the potential connection between immunomodulation in cardiology and the NLRP3 pathway is currently being explored in preclinical trials. Colchicine, cytokine-based approaches and SGLT2 inhibitors have emerged as promising agents. However, the conditions comprising IHD including atherosclerosis, coronary artery disease (CAD), myocardial infarction (MI) and ischemic cardiomyopathy/heart failure (iCMP/HF) are not equally amenable to immunomodulation with the respective drugs. Atherosclerosis, coronary artery disease and ischemic cardiomyopathy are affected by chronic inflammation, but the immunomodulatory approach to acute inflammation in the post-MI setting remains a pharmacological challenge, as detrimental and regenerative effects of myocardial inflammation are initiated in unison. The NLRP3 inflammasome lies at the center of cell mediated inflammation in IHD. Recent trial evidence has highlighted anti-inflammatory effects of colchicine, interleukin-based therapy as well as SGLT2i in IHD and that the respective drugs modulate the NLRP3 inflammasome.
No takes yet. Share an insight, caveat, or question.
Muhs et al. (2025) conducted a review in Ischemic Heart Disease. Anti-inflammatory therapies (colchicine, cytokine-based approaches, SGLT2 inhibitors) was evaluated. Anti-inflammatory therapies, including colchicine, interleukin-based therapy, and SGLT2 inhibitors, modulate the NLRP3 inflammasome and show promise in treating ischemic heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: